📋 Browse Articles

🔍 Search 📋 Browse 🏷️ Tags ❤️ Favourites ➕ Add 🧬 Extraction
Filtered by: APOA4 ✕ clear all
🏷️ Tags (31969 usages)
📦 Other 1510
▸ Other (850)
brain-derived neurotrophic factor (39)neuroplasticity (32)exercise (20)neurobiology (19)neurotoxicity (18)trkb (16)traditional chinese medicine (15)genetics (15)neurotrophic factors (14)hippocampal (13)central nervous system (12)neuroprotective (11)gut-brain axis (10)neurology (10)stroke (10)obesity (9)neurotrophic (9)psychology (9)dementia (9)zebrafish (8)bipolar disorder (8)neurotrophins (8)blood-brain barrier (8)aging (7)anti-inflammatory (7)neuropsychiatric disorders (7)memory (7)nanoparticles (7)neuropathic pain (7)neurotransmission (6)neurological disorders (6)mental health (6)neurotrophin (6)rats (6)stem cells (6)neuromodulation (6)astrocytes (6)neurodevelopmental disorders (6)psychiatry (6)cns (5)neuronal cells (5)meta-analysis (5)bioavailability (5)biochemistry (5)pathology (5)psychedelics (5)probiotics (5)amyloid-β (5)epilepsy (5)neurodevelopment (5)polymorphism (5)akt (5)aerobic exercise (5)astrocyte (4)nutrition (4)metabolomics (4)toxicity (4)neuroimmune (4)amyloid beta (4)myokines (4)brain health (4)rat model (4)physical exercise (4)neurotransmitter (4)ischemic stroke (4)neuropathology (4)physical activity (4)ngf (4)mesenchymal stem cells (4)neurodevelopmental disorder (4)physiological (3)overactive bladder (3)neuroblastoma (3)amyloid-beta (3)pathophysiology (3)extracellular vesicles (3)immune cells (3)microbiota (3)pi3k (3)neurotransmitters (3)pain management (3)camp (3)il-6 (3)neuronal survival (3)erk (3)hypoxia (3)interleukin-6 (3)estrogen (3)amyloid (3)neural development (3)intervention (3)neurobehavioral (3)voiding dysfunction (3)bioinformatics (3)metabolic (3)immunomodulation (3)ischemia (3)mitophagy (3)long-term potentiation (3)extracellular matrix (3)chemotherapy (3)brain function (3)psilocybin (3)microbiome (3)neuroendocrine (3)endocrine (3)cytokines (3)mouse model (3)neuropsychiatric (3)gastrointestinal (3)psychiatric disorders (3)sciatic nerve injury (3)anxiety disorders (3)hyperlipidemia (3)neurobiological (3)nerve growth factor (2)neuronal function (2)developmental toxicity (2)neural (2)gut health (2)biological (2)immunology (2)camkii (2)excitotoxicity (2)electrophysiological (2)urinary biomarkers (2)val66met polymorphism (2)behavioral (2)neuronal development (2)sleep deprivation (2)alpha-synuclein (2)neurological deficits (2)neuropsychiatry (2)empagliflozin (2)p2x4r (2)psychiatric disorder (2)cytokine (2)physiology (2)polyphenol (2)western diet (2)amnesia (2)calcium (2)multi-omics (2)gene therapy (2)neural stem cells (2)magnetic stimulation (2)exercise interventions (2)generalized anxiety disorder (2)serotonergic (2)yoga (2)microglial polarization (2)ischemic brain injury (2)mdd (2)in vivo (2)suicide (2)pathogenesis (2)anesthesia (2)cell death (2)substance use disorders (2)skeletal muscle (2)lead (2)radiotherapy (2)cardiology (2)5-ht (2)lactate (2)lipopolysaccharide (2)inflammatory (2)intermittent fasting (2)brain-gut axis (2)microgravity (2)mindfulness (2)hippocampal bdnf (2)hypertension (2)immunomodulatory (2)flavonoid (2)bone marrow (2)polyunsaturated fatty acids (2)ganoderma lucidum (2)pain (2)high-fat diet (2)gsk-3β (2)tissue engineering (2)adhd (2)il-10 (2)ampk (2)pink1 (2)microglial activation (2)muscle atrophy (2)amplitude (2)peripheral neuropathy (2)tissue plasminogen activator (2)metabolic health (2)healthy aging (2)wild (1)protein kinase (1)pesticide (1)brain abnormalities (1)immune (1)neural health (1)apoe (1)plant-based (1)cellular models (1)neurodevelopmental trajectories (1)synthesis (1)neurobehavioral toxicity (1)cas9 (1)histology (1)electrical stimulation (1)microglial dysfunction (1)hippocampal neurogenesis (1)plasticity (1)glutamatergic (1)phytochemical (1)urinary ngf (1)muscle weakness (1)gα (1)probdnf (1)stem cell therapy (1)nogo-a (1)schwann cell (1)diabetic neuropathy (1)blood biomarker (1)memantine (1)gs3kβ pathway (1)akt1 (1)nssi (1)ect (1)matrix metalloproteinases (1)nme3 (1)biology (1)platelet activation (1)whole-body vibration (1)gestation (1)neuronal plasticity (1)brain barriers (1)neurotransmitter systems (1)biomedicine (1)excipient selection (1)misa (1)genetic polymorphism (1)gsк-3β (1)bayesian network meta-analysis (1)addictive behaviors (1)motor neurons (1)chemical (1)tlr4 (1)psychotherapy (1)plga (1)atrazine (1)induced pluripotent stem cells (1)processed products (1)mental illness (1)nr2b (1)dendritic atrophy (1)domestication (1)adverse childhood experiences (1)hydrophobic interior (1)gestational intermittent hypoxia (1)neuropathy (1)calcineurin (1)sepsis-associated brain injury (1)gdnf (1)crispr (1)becn1 (1)appetite (1)derivatives (1)pediatric (1)nanocage (1)fibromyalgia (1)omega-3 fatty acids (1)paroxetine (1)mri (1)methyl donor (1)neuromodulatory (1)embryo development (1)case management (1)brain aging (1)bcl-2 (1)mettl3 (1)htr2c (1)psychological disorders (1)neurite outgrowth (1)erythropoietin (1)mastication (1)proteolytic processing (1)brain distribution (1)methylation (1)mental disorder (1)intestinal flora (1)pet (1)histone deacetylase (1)gut microbiome (1)proteome (1)klotho (1)attention deficit hyperactivity disorder (1)synthetic cannabinoid (1)human health (1)gene (1)metaplasticity (1)pkb (1)neurotherapeutics (1)sciatic nerve ligation (1)play behaviour (1)pediatric motor disorder (1)eeg (1)mood (1)cxcr4 (1)de novo lipogenesis (1)ultrasound (1)psychiatric therapies (1)nf-kappa b (1)excitatory synapses (1)hap1 (1)therapy (1)il6 (1)neat1 (1)pppar (1)surgical management (1)biochemical role (1)interleukins (1)agrochemical (1)calcium channels (1)neuronal activation (1)protein (1)pathophenotypes (1)glycation (1)dyspnea (1)genomics (1)epidemiology (1)acetylcholinesterase (1)polymorphic variants (1)thiazole (1)perinatal programming (1)neural pathways (1)degradation (1)uveitis (1)synthetic opioid (1)nanocarriers (1)vitamin d3 (1)metabolic dysfunction (1)astroglia (1)pparα (1)pfas (1)glial cells (1)ace2 (1)muscle (1)network (1)uhplc-q-tof-ms/ms (1)sglt2 inhibitor (1)biological aging (1)biochemical analysis (1)astrobiology (1)microbiota-gut-brain axis (1)local translation (1)wharton's jelly (1)essential oil (1)upper motor neuron (1)vulnerability (1)visceral pain (1)adolescence (1)histological damage (1)amyk (1)systemic (1)neural alterations (1)maoa (1)neuroprotectants (1)metabolic flexibility (1)polycystic ovary syndrome (1)neuroprotectors (1)trk (1)genotype (1)migration (1)brain metastases (1)jak2 (1)neuron-microglia interactions (1)behavioral disorders (1)hsd10 (1)aging brain (1)neurotoxicants (1)cell biology (1)neurological function (1)pkr inhibition (1)mict (1)antipsychotic (1)child mental disorder (1)blood brain barrier (1)stat3 (1)ipsc-derived neurons (1)cannabis (1)sepsis-associated encephalopathy (1)functional (1)olfaction (1)protein design (1)neurons (1)genetic background (1)axon growth (1)metformin (1)atf4 (1)blood-based biomarkers (1)multisystem (1)neutrophil extracellular traps (1)cd4 (1)phenolic acid (1)tissue inhibitors of metalloproteinases (1)inflammasome (1)obstetrics (1)fat oxidation (1)ondansetron (1)physical function (1)ipsc (1)ythdf1 (1)glymphatic function (1)immune system (1)nutritional strategies (1)anesthetics (1)ich (1)electroencephalogram (1)rodent models (1)in vivo study (1)phthalates (1)physiotherapy (1)nlrp3 (1)electroporation (1)older adults (1)sexual dysfunction (1)mice (1)sesquiterpenoid (1)fibrinolytic (1)gut-brain interactions (1)n-acetylcysteine (1)body weight (1)mfn2 (1)rat brain (1)hiit (1)inflammatory process (1)spinal disc (1)pacap (1)opioid use (1)ayahuasca (1)genetic risk factor (1)pkc delta (1)endothelial cells (1)lactation (1)hepatocellular carcinoma (1)cell viability (1)necrotic cell death (1)offspring behavior (1)cholinergic dysfunction (1)neurobiomarkers (1)neurotrophin-3 (1)canagliflozin (1)anxiety disorder (1)orthopedic fixation (1)neurodevelopmental biology (1)fragile x syndrome (1)npas4 (1)mesoporous silica (1)cardioprotective (1)hydrocephalus (1)neurological disorder (1)microbiomics (1)nanotherapeutics (1)tubulin (1)neuroinflammatory signalling (1)sineup (1)p75ntr (1)8-iso-pgf2α (1)diabetic neuropathic pain (1)lumbrokinase (1)nlrp3 inflammasome (1)neural organoid (1)neurobiochemistry (1)photoplethysmography (1)cadmium (1)fibroblast-growth factor-21 (1)bulimia (1)calcium-binding protein (1)nursing intervention (1)lipid rafts (1)hallucinogens (1)immune checkpoint (1)trka (1)biological markers (1)social interaction (1)systemic inflammation (1)passive smoking (1)atp production (1)nad (1)biological pathways (1)endocrine disorder (1)decline (1)anxiolytic (1)translation (1)kinases (1)personalized medicine (1)protein formulation (1)vagus nerve (1)carbon dots (1)aerobic (1)in vivo efficacy (1)polyphenols (1)motivational behaviors (1)gonadal hormones (1)nanotechnology (1)neurological growth (1)mitogen-activated protein kinase (1)cannabidiol (1)neuronal degeneration (1)oxidative damage (1)public health (1)radiation-induced brain injury (1)cholinergic (1)therapeutics (1)meditation (1)salmon (1)gut brain axis (1)chemokines (1)toxoplasma gondii (1)omics (1)bdnf/trkb pathway (1)neuroanatomy (1)hepatoprotective (1)nanofibers (1)growth factor (1)dietary triglyceride (1)eating behavior (1)tgf-β (1)homing (1)neuropsychology (1)visual stimulation (1)histone (1)t cells (1)diabetic ischemic brain injury (1)bax (1)behavioral performance (1)prkn (1)metabolic alterations (1)stem cell (1)axon guidance (1)sumoylation (1)acd (1)erbb4 inhibitor (1)two-hit model (1)perk (1)tug1 (1)gene activation (1)tea polyphenols (1)tcm (1)developmental neurotoxicity (1)hormonal (1)plasmin (1)emotion axis (1)bdnf pathway (1)mmp-9 (1)heavy metal (1)histologic analysis (1)platelet factor 4 (1)fisetin (1)neurobehavioral deficits (1)anaerobic exercise (1)hypoxanthine (1)motor function (1)hippocampal neurons (1)psychedelic (1)nutritional psychiatry (1)nerve injury (1)brain-derived neurotrophic factors (1)behaviors (1)mct oil (1)hippocampal plasticity (1)hippocampal development (1)kcc2 (1)peripheral blood mononuclear cells (1)ecb (1)pcl (1)exercise intervention (1)glial scarring (1)ovine (1)lung-brain axis (1)hyperventilation syndrome (1)hbv (1)endocannabinoid pathways (1)geriatrics (1)neonatal brain proteomics (1)muscle pain (1)etiology (1)weightlessness (1)biodegradable materials (1)ho-1 (1)pain subtypes (1)cxcl12 (1)bdnf signalling (1)p2x7r (1)salivary gland (1)cholesterol (1)vitamin d (1)behavior (1)nmda (1)genetic (1)sociodemographic factors (1)neuroprotective properties (1)ethanol (1)oral delivery (1)suicidal ideation (1)neurophysiology (1)synovial fibroblasts (1)translational (1)bioactivity (1)function (1)neural stimulation (1)muscle function (1)ophthalmology (1)gene-tbi interactions (1)macrophages (1)cannabinoid (1)fatty acids (1)piezoelectric (1)tms (1)hepatic encephalopathy (1)mood disorders (1)tph2 (1)cardiometabolic disease (1)psychological (1)single-nucleotide variants (1)schwann cells (1)euglena gracilis (1)inflammatory bowel disease (1)intestinal barrier (1)emotional disorders (1)hyperammonemia (1)5-ht pathway (1)app (1)sleep (1)olfactory system (1)neurovegetative (1)beta-glucan (1)lithium chloride (1)psychobiotics (1)brainstem (1)neuronal growth (1)glioma (1)apolipoprotein e (1)psychotropic (1)substance use disorder (1)neurobiological alterations (1)dendritic morphology (1)b-cell lymphoma 2 (1)puberty (1)cmd (1)electromagnetic field (1)neurochemicals (1)pgc1α (1)low back pain (1)dheas (1)biological sciences (1)intranasal delivery (1)neurotrophic hypothesis (1)cbt (1)sik1 (1)magnetically targeted (1)motor neuron disease (1)visceral hypersensitivity (1)psychiatric genetics (1)drp1 (1)butyrate (1)six3 (1)triclocarban (1)proteomic clustering (1)pharmaceutical (1)cellular nerve damage (1)parkin (1)sciatic nerve (1)pediatrics (1)sepsis (1)pcr (1)traditional uyghur medicine (1)murine model (1)bace1 (1)liquid crystalline (1)gwas (1)neuroblastoma cells (1)signalling pathway (1)brain oxygenation (1)paxillin (1)inflammatory markers (1)neural damage (1)mass spectrometry (1)sleep-promoting (1)monocytes (1)mh (1)sex hormones (1)brain biomarkers (1)immune activation (1)glutamatergic system (1)akt pathway (1)pituitary gland (1)neurochemistry (1)phytochemical analysis (1)plant (1)behavioral deficits (1)tnfα (1)psychiatric (1)peripheral nerve injury (1)clearance system (1)acrylamide (1)behavioral dysfunction (1)gut-hippocampus axis (1)neonatal development (1)vitamin c (1)ppparα (1)uflc-q-tof-ms/ms (1)stagnant phlegm syndrome (1)neurodelivery (1)cav1 (1)metabolic processes (1)gpr40 (1)na/k-atpase (1)nuclear translocation (1)nanoemulsion (1)pericytes (1)p2y1r (1)next-generation sequencing (1)neuroactive lignan (1)food intake (1)neuronal injury (1)muscle denervation (1)inflammatory pathways (1)sox5 (1)herbicide (1)neuroma (1)maya-mestizo population (1)dexras1 (1)msc (1)microcystin (1)amyloid plaque (1)cardiometabolic (1)rat models (1)val66met (1)rock1 (1)plasma technology (1)statins (1)bdnf-trkb pathway (1)mendelian randomization (1)protein kinase b (1)neural plasticity (1)oxidative balance (1)spleen-kidney deficiency (1)prisma (1)metabolic function (1)proinflammatory cytokines (1)antioxidative (1)multiple system atrophy (1)neurobehavior (1)mcao (1)herbal medicine (1)eating disorders (1)brain plasticity (1)hyperglycemia (1)visual function (1)peripheral brain-derived neurotrophic factor (1)lithium (1)dry eye model (1)hepatocyte (1)tnf-α (1)proteases (1)neurological health (1)steroid hormones (1)dendritic spine (1)uhplc-qtof-ms (1)social memory (1)perineuronal networks (1)phytoestrogen (1)childhood obesity (1)lc-ms (1)microvesicles (1)caspase-4 (1)inflammaging (1)muscle-brain axis (1)spions (1)therapeutic implications (1)adolescent brain (1)rotenone (1)metabolic syndrome (1)no (1)lineage (1)neural network (1)phq-9 (1)lipid-lowering (1)gene mutations (1)biochemical (1)pka (1)central sensitization (1)matrix metalloproteases (1)risperidone (1)morphological deficits (1)panax ginseng (1)bioprinted (1)neurotoxicity-associated metabolic alterations (1)polymorphisms (1)minocycline (1)ntrk (1)lcn2 (1)behavioral science (1)liver injury (1)pituitary (1)biophysics (1)cholinergic function (1)orthopedics (1)neural tissue (1)hippocampal injury (1)gastric ulcer (1)vitality (1)space medicine (1)igf-1 (1)intrinsic capacity (1)central nervous system disorders (1)neurodevelopmental studies (1)single-nucleotide polymorphisms (1)fasd (1)polygalae radix (1)exerkines (1)pathophysiological interactions (1)walking (1)chemobrain (1)neural function (1)ingestion (1)bangladeshi population (1)urodynamics (1)aβ plaques (1)immuno-modulation (1)pathway (1)neuroendocrinology (1)supplementation (1)brain tissue (1)cardiotoxicity (1)mglur5 (1)acetylation (1)microplastic (1)therapeutic perspectives (1)methylxanthine (1)naphthoquinone (1)myokine (1)analgesia (1)gst (1)choroid plexus (1)plasma biomarkers (1)glutamatergic pathways (1)biomaterials (1)global health (1)inhibitor (1)
⚗️ Metals 1041
▸ Metals — Other (620)
neuroscience (64)cognitive function (30)synaptic plasticity (25)stress (15)antidepressant (14)pharmacology (11)cognitive dysfunction (10)toxicology (9)cognition (9)serotonin (8)major depressive disorder (7)molecular biology (7)spinal cord injury (7)prefrontal cortex (7)chronic stress (6)autism spectrum disorder (6)chronic pain (6)exosomes (6)ptsd (6)cognitive (6)irisin (5)pregnancy (5)memory impairment (5)network pharmacology (5)cognitive performance (5)endoplasmic reticulum stress (5)neuropharmacology (5)environmental enrichment (4)homeostasis (4)oncology (4)neuroprotective effects (4)traumatic brain injury (4)molecular mechanisms (4)depressive disorder (4)cardiovascular (4)psychopharmacology (4)neuroregeneration (4)resveratrol (4)post-traumatic stress disorder (4)chitosan (4)affective disorders (3)osteoporosis (3)insomnia (3)high-intensity interval training (3)neurobiological mechanisms (3)serum (3)treatment-resistant depression (3)mirna (3)nerve regeneration (3)animal model (3)transcriptomics (3)acupuncture (3)sarcopenia (3)molecular dynamics (3)molecular (3)molecular docking (3)autism (3)rehabilitation (3)electroconvulsive therapy (3)regenerative medicine (3)bioactive compounds (3)prenatal stress (3)melatonin (3)cums (2)tau protein (2)cancer progression (2)er stress (2)glucocorticoid receptor (2)insulin resistance (2)preclinical (2)metabolic regulation (2)quality of life (2)docosahexaenoic acid (2)pharmacogenomics (2)neuroprotective mechanisms (2)gene regulation (2)heart failure (2)alcohol consumption (2)amyotrophic lateral sclerosis (2)ketogenic diet (2)neural circuitry (2)antidepressants (2)trauma (2)retina (2)neurovascular (2)mir-34a-5p (2)ginsenosides (2)stroke recovery (2)transcriptome (2)transcranial magnetic stimulation (2)systematic review (2)molecular pathways (2)regulatory mechanisms (2)executive function (2)postoperative care (2)neuroprotective effect (2)corticosterone (2)post-stroke depression (2)retinal ganglion cells (2)premature ejaculation (2)cognitive recovery (2)selenium (2)learning (2)pharmacological (2)glucagon-like peptide-1 (2)functional recovery (2)circadian rhythms (2)endocrine disruptors (2)early-life stress (2)axonal regeneration (2)naringenin (2)cognitive deficits (2)endoplasmic reticulum (2)alcohol (2)depressive behaviors (2)peripheral nerve regeneration (2)nmda receptor (2)cognitive health (2)cortisol (2)cytoskeleton (2)postoperative cognitive dysfunction (2)infralimbic cortex (2)cerebrum (2)cortical neurons (2)synaptic dysfunction (2)molecular targets (2)benzalkonium chloride (2)prebiotics (2)mild cognitive impairment (2)ethnopharmacology (2)cognitive functions (2)regeneration (2)tau (1)viral infections (1)stress responses (1)physicochemical characterization (1)brain immunity (1)correction (1)retinoic acid (1)post-translational modification (1)exposure (1)lucidenic acid a (1)hepatic steatosis (1)dietary regulation (1)nerve conduits (1)environmental pollutants (1)perigestational opioid exposure (1)meta-regression (1)mechanosensory hair cells (1)hippocampal ca2 region (1)neural precursors (1)photoreceptors (1)anaerobic glycolytic flux (1)respiratory (1)randomized controlled trials (1)ischemic postconditioning (1)molecular changes (1)growth cones (1)total abdominal irradiation (1)cardiovascular disease (1)aggression (1)gold nanoparticles (1)circrna (1)preclinical evidence (1)traumatic injury (1)dopamine d2 receptor (1)progressive (1)psychological trauma (1)drug metabolism (1)neural structure (1)synaptic transmission (1)laquinimod (1)preterm birth (1)resilience (1)peptide design (1)fermented food (1)spatial learning (1)complications (1)allergic contact dermatitis (1)particulate matter (1)corticospinal tract (1)chronic restraint stress (1)cerebellum (1)hepatitis b virus (1)copd (1)post-stroke cognitive impairment (1)tryptophan metabolism (1)ginsenoside (1)auricular vagus nerve stimulation (1)biosynthesis (1)scoping review (1)vascular endothelium (1)opioid prescription (1)mir-381-3p (1)learning-memory (1)fetal alcohol spectrum disorders (1)emotion perception (1)hippocampal structure (1)cell communication (1)sedative-hypnotic effects (1)amniotic fluid stem cell (1)cardiovascular disorders (1)nerve guidance conduits (1)regulatory network (1)synaptic impairment (1)peroxisome proliferator-activated receptor alpha (1)neurocognitive impairment (1)aquatic ecosystems (1)fibronectin type iii domain-containing protein 5 (1)phosphorylated tau (1)oxygen-glucose deprivation (1)chronicity (1)intracerebral hemorrhage (1)osteosarcopenia (1)behavioral responses (1)anorexia (1)selective serotonin reuptake inhibitors (1)stable love relationships (1)psychological treatment (1)hippocampal regeneration (1)redox homeostasis (1)neuroprotective molecules (1)neurovascular plasticity (1)neuropeptide (1)irradiation (1)hemorheological parameters (1)cellular mechanisms (1)cognitive flexibility (1)astrocytic disruption (1)alcohol dependence (1)stroke treatment (1)irritable bowel syndrome (1)seizure susceptibility (1)immune reactions (1)tumor necrosis factor alpha (1)mirnas (1)menopausal (1)microbiota dysbiosis (1)bed rest (1)nicotine (1)bone loss (1)cubosome formulation (1)post traumatic stress disorder (1)vascular dysfunction (1)hyperandrogenism (1)pd-1 (1)hippocampal neuronal apoptosis (1)prenatal exposure (1)pyroptosis (1)withaferin a (1)glycolysis (1)microenvironment (1)redox balance (1)circadian rhythm (1)olfactory exposure (1)nose-to-brain delivery (1)neurocognitive outcomes (1)sex differences (1)neuro-osteogenic microenvironment (1)acute ischemic stroke (1)psychedelic drugs (1)sinomenine (1)secretory protein (1)maladaptive neuroplasticity (1)facial recognition (1)stress disorder (1)carnosine (1)synaptic deficits (1)mir-146a-3p (1)regulation (1)ferritin (1)protein secretion (1)scopolamine-induced amnesia (1)randomized controlled trial (1)principal component analysis (1)appetite regulation (1)psychiatric comorbidities (1)environmental toxicology (1)gynecology (1)hif-1α-epo/camp-creb-bdnf pathway (1)depressive states (1)learning process (1)neural regeneration (1)cardiac arrest (1)psychological outcomes (1)affective states (1)gut dysbiosis (1)long non-coding rnas (1)prefrontal-limbic connectivity (1)psychological reaction (1)extremely low-frequency magnetic field (1)clinical assessment (1)microglial exosomes (1)neurotoxicology (1)epileptogenesis (1)clinical trial (1)anabolic-androgenic steroid (1)ethnic medicine (1)mitochondrial calcium uniporter (1)weight loss (1)amitriptyline (1)stress responsivity (1)serotonergic circuit (1)lps-induced depression (1)locomotion (1)steroidal saponin (1)aquatic organisms (1)correlation (1)drug response (1)transcriptomic (1)long non-coding rna (1)rheumatoid arthritis (1)rem theta (1)absorption (1)chronic heart failure (1)fentanyl administration (1)molecular toxicology (1)vascular cognitive impairment (1)motor impairment (1)adipose-derived stem cells (1)neuro-related disorders (1)emotional regulation (1)restraint stress (1)regenerative capabilities (1)antinociceptive (1)cerebral palsy (1)cerebral infarction (1)normal pressure hydrocephalus (1)positron emission tomography (1)bioengineered delivery system (1)adenosine (1)connexin43 (1)immunoregulation (1)comorbid (1)cerebrovascular disease (1)in silico (1)moderate-intensity continuous training (1)cognitive improvement (1)stress-induced depressive behaviors (1)drug delivery (1)lycopene delivery (1)host-virus interactions (1)phosphatidic acid (1)sirt1 (1)neuroserpin (1)heat stress (1)macular degeneration (1)medial prefrontal cortex (1)intranasal drug delivery (1)early diagnosis (1)rem sleep behavior disorder (1)seizures (1)psychosocial (1)prenatal supplementation (1)adeno-associated virus (1)neurotoxic effects (1)proanthocyanidins (1)neurocognitive (1)anti-inflammatory effects (1)gestational opioid exposure (1)nociceptive sensitization (1)stress axis regulation (1)anthocyanins (1)pruritus (1)phlorotannin (1)high intensity interval training (1)prosopis cineraria (1)psychosis (1)constipation (1)psychedelic compounds (1)delphinidin (1)myostatin (1)triterpenoid saponins (1)limbic structures (1)osteoblast (1)bdnf expression (1)poly(lactic-co-glycolic acid) (1)korean population (1)neuroimmune crosstalk (1)chronic diseases (1)low birthweight (1)α7 nicotinic acetylcholine receptor (1)protein quality control (1)peptide hydrogel (1)fecal calprotectin (1)metabolic adaptation (1)single-cell transcriptomics (1)cell differentiation (1)neurogenic bladder (1)hippocampal synaptic proteins (1)chemoresistance (1)herb pair (1)chronotropic incompetence (1)autism-like behavior (1)testicular health (1)aggressive behavior (1)allodynia (1)obstructive sleep apnea (1)opioid overdose (1)gold coast criteria (1)n-methyl-d-aspartate receptor (1)psychological stress (1)betulinic acid (1)retinal degeneration (1)depressive pathologies (1)traumatic event (1)ros (1)extremely low-frequency electromagnetic field (1)cognitive impairments (1)chronic toxoplasmosis (1)dacomitinib (1)serotonin 5-ht2a receptor (1)pulmonary fibrosis (1)psychostimulant (1)chronic unpredictable mild stress (1)tobacco smoke (1)radiofrequency electromagnetic fields (1)fetal brain development (1)sedative-hypnotic effect (1)social buffering (1)depressive disorders (1)epigenetic dysregulation (1)neuroimmune circuits (1)childhood growth restriction (1)resolvin d1 (1)molecular design (1)glp-1 receptor agonists (1)brain-gut homeostasis (1)neurotrophic adaptation (1)liver failure (1)creb pathway (1)diclofenac (1)n6-methyladenosine (1)immune mechanisms (1)laminin (1)cerebrovascular accidents (1)suicide attempt (1)neural repair (1)synaptic (1)adverse outcome pathway (1)opioid receptors (1)memory impairments (1)fibrotic remodeling (1)neuronal communication (1)appetite control (1)outcomes (1)hypothalamus-pituitary-adrenal axis (1)serum bdnf levels (1)lung homeostasis (1)perioperative neurocognitive disorders (1)cognitive training (1)melatonin receptor (1)adolescent social isolation stress (1)cognitive therapy (1)fear memory (1)osseointegration (1)musculoskeletal system (1)colitis (1)autoimmune uveitis (1)light treatment (1)cerebral protection (1)neurotrophic dysregulation (1)ingredient (1)developmental neurotoxicology (1)transcriptional changes (1)neurosteroids (1)environmental conditions (1)orthostatic hypotension (1)pathological microenvironment (1)autologous serum (1)physiological resilience (1)spatial transcriptomics (1)function recovery (1)age-related macular degeneration (1)seizure (1)mangiferin (1)preclinical models (1)herpes simplex virus (1)exosome-based therapy (1)peptides (1)melanocortin (1)tau phosphorylation (1)tumor necrosis factor (1)eicosapentaenoic acid (1)neural circuit (1)hypothalamic-pituitary-adrenal axis (1)brain structure (1)phosphatidylserine (1)irák1 (1)colorectal cancer (1)perinatal depression (1)learning ability (1)allostatic load (1)adolescent depression (1)creatine supplementation (1)affective dysfunction (1)non-pharmacological interventions (1)personal care products (1)diagnosis (1)unfolded protein response (1)antidepressant mechanisms (1)cerebral hemorrhage (1)autophagic pathway (1)nanocomposite hydrogel (1)causal relationship (1)fear extinction (1)neuropeptide s (1)nociceptive responses (1)dpd-4 inhibitors (1)traumatic stress disorder (1)colon cancer (1)tau hyperphosphorylation (1)tyrosine kinase receptor b (1)ecosystems (1)reproductive physiology (1)stress regulation (1)motor learning (1)disease-syndrome combined model (1)methionine-choline-deficient diet (1)s-nitrosylation (1)neurocognitive disorders (1)postmenopausal women (1)neural recovery (1)kaempferol (1)postoperative delirium (1)receptor (1)social cognition (1)neurocognition (1)environmental (1)hcortisolaemia (1)integrated stress response (1)systemic effects (1)antiretroviral therapy (1)adenosine receptor (1)late-life cognitive decline (1)traumatic memories (1)energy homeostasis (1)antidepressant effect (1)physiological adaptations (1)inflammatory responses (1)tissue architecture (1)vascularization (1)neuroimmune responses (1)human respiratory syncytial virus (1)vision loss (1)rapid antidepressant effects (1)tau pathology (1)drug release (1)signal peptide (1)noncommunicable diseases (1)electrospun (1)alcohol-induced cognitive impairment (1)vasoactive intestinal polypeptide (1)cognitive behavior (1)hypothalamic pituitary adrenal axis (1)machine learning (1)hypothalamic-pituitary adrenal axis (1)parkinsonism (1)cognitive resilience (1)impairment (1)experimental autoimmune uveoretinitis (1)precursor state (1)hmg-coa reductase inhibitors (1)tumor necrosis factor-α (1)relationship (1)cognitive aging (1)clinical psychology (1)antidepressant activity (1)optic nerve injury (1)mechanistic (1)vascular maturation (1)biomechanics (1)aerospace medicine (1)oncogenic drivers (1)differentiation (1)resistance training (1)paraventricular nucleus (1)ecotoxicity (1)synaptic homeostasis (1)environmental concern (1)bdnf/creb pathway (1)creb phosphorylation (1)mood dysregulation (1)nitrous oxide (1)dentate gyrus (1)paternal exposure (1)behavioral despair (1)nicotine exposure (1)lactobacillus plantarum (1)electroacupuncture (1)female mice (1)fetal neural development (1)tropomyosin receptor kinase b (1)environmental contaminants (1)differentiation protocols (1)magnetic resonance imaging (1)reward processing (1)arsenic (1)steroid effects (1)diosgenin (1)stress hormone (1)oral administration (1)hemorheology (1)synaptic models (1)reversal learning (1)synaptic signaling (1)cognitive outcomes (1)presynaptic (1)magnetic field exposure (1)ischemia reperfusion injury (1)nitric oxide (1)toxoplasmosis (1)tyrosine kinase inhibitors (1)acute hepatitis (1)glucagon-like peptide-1 receptor agonists (1)somatosensory cortex (1)serotonin pathway (1)biological effects (1)cyanidin (1)breast cancer (1)
💊 Drugs 4

🔍 Filters

997 articles with selected tags
Sachiko Araki, Sataro Goto · 2003 · Experimental gerontology · Elsevier · added 2026-04-24
Alterations of serum apolipoproteins A-I (apo A-I) and A-IV and their mRNAs in young and old mice by fasting and refeeding were investigated by polyacrylamide gel elecrophoresis and Northern blot, res Show more
Alterations of serum apolipoproteins A-I (apo A-I) and A-IV and their mRNAs in young and old mice by fasting and refeeding were investigated by polyacrylamide gel elecrophoresis and Northern blot, respectively. After fasting for three days, serum apo A-I concentration in young mice (6-9 month-old) was increased about 1.5 fold while that of old animals (25-34 month-old) did not change significantly. Apo A-I mRNA was increased about 3-fold and 1.7-fold in the liver and small intestine of the young mice, respectively. The increase in old animals was not more than 1.5-fold in both tissues. The serum apo A-IV was elevated 2-fold and its mRNA was markedly (ca. 50-fold) induced in the liver of fasted young mice, whereas the increase of the mRNA was less than 2-fold in the small intestine. In contrast, induced levels of the protein in serum and its mRNA in both tissues were much less in old mice. In view of the roles of apo A-I and A-IV in triglyceride mobilization and reverse cholesterol transport, the present findings suggest that the reduced induction of the mRNAs for these apolipoproteins in the liver by prolonged fasting and possibly under normal feeding conditions can be an important factor in the impaired immobilization of lipid in old animals, and may, in turn, have implication in age-related diseases such as coronary, cerebral and other vascular disorders. Show less
no PDF DOI: 10.1016/s0531-5565(03)00038-x
APOA4
Patrick Tso, Guifa Xu · 2003 · Wei sheng yan jiu = Journal of hygiene research · added 2026-04-24
Although many exciting functions of Apolipoprotein A-IV(apo-A IV) have been proposed, this review focuses on its unique role in regulating food intake. Apo-A IV is a glycoprotein produced by human int Show more
Although many exciting functions of Apolipoprotein A-IV(apo-A IV) have been proposed, this review focuses on its unique role in regulating food intake. Apo-A IV is a glycoprotein produced by human intestine and rodent intestine and liver, but the small intestine is the major organ responsible for the circulating apo-A-IV. Our Laboratory recently demonstrated that apo-A IV protein and apo-A IV mRNA were present in rat hypothalamus. Intestinal apo-A IV synthesis is markedly stimulated by fat absorption and the formation of chylomicrons. Intestinal apo-A IV synthesis is also enhanced by the peptide tyrosine-tyrosine. The inhibition of food intake by apo-A IV is mediated centrally. Apo-A IV likely plays a role in the short-term regulation of food intake. Other evidence suggests that apo-A IV may also be involved in the long-term regulation of food intake and body weight. Reduction of apo-A IV in response to lipid feeding in both animal and humans that chronically consume a high-fat diet may explain in part why the chronic ingestion of a high-fat diet predisposes to obesity. Show less
no PDF
APOA4
Steve Martin, Viviane Nicaud, Steve E Humphries +2 more · 2003 · Biochimica et biophysica acta · Elsevier · added 2026-04-24
The aim of this study was to investigate the influence of APOA5 variants on fasting lipids and to the response to both an oral fat tolerance test (OFTT) and an oral glucose tolerance test (OGTT). The Show more
The aim of this study was to investigate the influence of APOA5 variants on fasting lipids and to the response to both an oral fat tolerance test (OFTT) and an oral glucose tolerance test (OGTT). The association of two APOA5 SNPs [S19W (SNP5), -1131T>C (SNP3)] and an APOA4/A5 intergenic SNP [-12238T>C (SNP4)] were examined in healthy young men (n=774) who had undergone both an OFTT and an OGTT. Both -1131T>C and S19W rare alleles were associated with triglyceride (TG)-raising effects (11%, P=0.008; 21% (in cases), P<0.026, respectively) and showed additive effects on TG. None of the variants influenced the responsiveness to the OFTT after correcting for baseline TG. Homozygosity for the -12238T>C rare allele was associated with higher waist to hip ratio (P<0.0006), systolic blood pressure (P=0.012) and AUC and peak of insulin after OGTT (P=0.003 and P=0.027, respectively), traits that define the metabolic syndrome. Our results strongly support the role of APOA5 in determining plasma TG levels in an age-independent manner and highlight the importance of the APOC3/A4/A5 gene cluster in both TG and metabolic homeostasis. Show less
no PDF DOI: 10.1016/s0925-4439(03)00033-4
APOA4
Wai-Man R Wong, Emma Hawe, Lai K Li +5 more · 2003 · Circulation research · added 2026-04-24
The impact of common variants in the apolipoprotein gene cluster (APOC3-A4-A5) on prospective coronary heart disease (CHD) risk was examined in healthy UK men. Of the 2808 men followed over 9 years, 1 Show more
The impact of common variants in the apolipoprotein gene cluster (APOC3-A4-A5) on prospective coronary heart disease (CHD) risk was examined in healthy UK men. Of the 2808 men followed over 9 years, 187 had a clinically defined CHD event. Examination of 9 single nucleotide polymorphisms (SNPs) in this group revealed that homozygotes for APOA4 S347 had significantly increased risk of CHD [hazard ratio (HR) of 2.07 (95%CI 1.04 to 4.12)], whereas men homozygous for APOC3 1100T were protected [HR 0.28 (95%CI 0.09 to 0.87)]. In stepwise multiple regression analysis, after entering all the variants and adjusting for established risk factors APOA4 T347S alone remained in the model. Using all nine SNPs, the highest risk-estimate haplotypes carried APOA4 S347 and rare alleles of the two flanking intergenic markers. The protective effect of APOC3 1100T could be explained by negative linkage disequilibrium with these alleles. To determine the association of APOA4 T347S with apoAIV levels, the relationship was examined in 1600 healthy young European men and women. S347 homozygotes had significantly lower apoAIV plasma levels (13.64+/-0.59 mg/dL) compared with carriers of the T347 allele (14.90+/-0.12 mg/dL) (P=0.035). These results demonstrate that genetic variation in and around APOA4, independent of the effects of triglyceride, is associated with risk of CHD and apoAIV levels, supporting an antiatherogenic role for apoAIV. Show less
no PDF DOI: 10.1161/01.RES.0000069688.94567.7A
APOA4
G Q Wang, M DiPietro, K Roeder +4 more · 2003 · Annals of human genetics · added 2026-04-24
Genetic variation in several genes involved in lipid metabolism is known to affect population variation in quantitative lipid risk factor profiles for coronary heart disease (CHD). The apolipoprotein Show more
Genetic variation in several genes involved in lipid metabolism is known to affect population variation in quantitative lipid risk factor profiles for coronary heart disease (CHD). The apolipoprotein A-IV gene (APOA4) is one such candidate gene. We genotyped five polymorphisms in the APOA4 gene (codon 127, codon 130, codon347, codon 360 and 3' VNTR) and investigated their impact on plasma lipid trait levels in three populations comprising 604 U.S. non-Hispanic Whites (NHWs), 408 U.S. Hispanics and 708 Nigerian Blacks. Cladistic analysis was carried out to identify 5-site haplotypes that were associated with significant phenotypic differences in each population. The distribution of APOA4 genotypes was significantly different between ethnic groups. The Africans were monomorphic for two of the five sites (codons 130 and 360), but possess a unique 12 bp insertion that was not observed in NHWs and Hispanics. Due to linkage disequilibrium between the sites, only 6 haplotypes were observed in NHWs and Hispanics, and 4 in Africans. Several gender-and ethnic-specific associations between genotypes and plasma lipid traits were observed when single sites were used. Several haplotypes were identified by cladistic analysis that may carry functional mutations that affect plasma lipid trait levels. Show less
no PDF DOI: 10.1046/j.1469-1809.2003.00023.x
APOA4
M Fiegenbaum, M H Hutz · 2003 · International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity · Nature · added 2026-04-24
To investigate associations and gene-environment interactions of APOA-IV gene polymorphisms with obesity-related phenotypes in a Brazilian population. A total of 391 individuals (171 men and 220 women Show more
To investigate associations and gene-environment interactions of APOA-IV gene polymorphisms with obesity-related phenotypes in a Brazilian population. A total of 391 individuals (171 men and 220 women) were genotyped for Xbal, Thr347Ser and Gln360His polymorphisms by PCR-RFLP methods. Adjusted body mass index (BMI) and waist circumference (WC) were compared among genotypes/haplotypes by unpaired t-test or analysis of variance. Gene-environment interactions were tested by analysis of variance using a general linear model. Analysis of the APOA-IV gene variants separately showed that X*2 and 347Ser alleles were associated with higher BMI (P=0.02 for both polymorphisms). Haplotype analysis confirmed this association. For these polymorphisms, the effect on BMI appeared to depend on smoking status (test for interaction, P=0.007 and 0.02, respectively), the Thr347Ser variant was associated with a BMI increase in smokers only (P=0.002). At the single-locus level no association was observed between 360His allele and BMI; however, haplotype analyses showed an association of this gene variant and higher BMI. A trend for association with WC (P=0.05) was observed in male carriers of the 360His allele. The effect of this polymorphism also depended on smoking status (test for interaction, P=0.018). Nonsmoker male carriers of the 360His allele had a larger waist circumference than homozygotes for the Gln allele (P=0.003). Our data suggest that the APOA-IV gene polymorphisms investigated are associated with obesity-related traits. The effects of X*2 and 347Ser variants on BMI and the 360His variant on waist circumference depended on smoking status. Show less
no PDF DOI: 10.1038/sj.ijo.0802256
APOA4
Toshinori Kamisako, Hiroshi Ogawa · 2003 · Hepatology research : the official journal of the Japan Society of Hepatology · Elsevier · added 2026-04-24
The purpose of this study is to evaluate the effect of bile duct ligation (BDL) on changes of lipoprotein metabolism and hepatic gene expressions that are important for cholesterol metabolism. In male Show more
The purpose of this study is to evaluate the effect of bile duct ligation (BDL) on changes of lipoprotein metabolism and hepatic gene expressions that are important for cholesterol metabolism. In male rats serum, very low-density lipoprotein cholesterol, low-density lipoprotein cholesterol and apolipoproteins B and E increased after 5 days of BDL compared with those of sham operation (control) group. Serum apolipoprotein A-IV concentration in the BDL group was lower than that in the control group. In both groups, there was no difference in hepatic lipid concentrations. Hepatic mRNA expressions of scavenger receptor B1, microsomal triglyceride transfer protein (mtp), HMG-coA reductase, cholesterol 7alpha-hydroxylase and multidrug resistance gene product 2 in the BDL group were significantly higher than that in the control group. The adipocyte determination and differentiation 1 mRNA expression in the BDL group was significantly lower than that in the control group. abcg5 and abcg8 mRNA expressions were remarkably decreased in the BDL group. In conclusion, in obstructive jaundice, metabolism of lipoprotein and proteins that are important for lipid metabolism are drastically changed probably for maintaining the hepatic lipid concentration. The remarkable down-regulation of the abcg5 and abcg8 may be an adaptive change reflecting the inability of biliary cholesterol excretion. Show less
no PDF DOI: 10.1016/s1386-6346(02)00248-6
APOA4
Simona Stan, Edgard Delvin, Marie Lambert +2 more · 2003 · Biochimica et biophysica acta · Elsevier · added 2026-04-24
Apolipoprotein (apo) A-IV, first identified 28 years ago as a plasma lipoprotein moiety, is now known to participate in the regulation of various metabolic pathways. It is synthesized primarily in the Show more
Apolipoprotein (apo) A-IV, first identified 28 years ago as a plasma lipoprotein moiety, is now known to participate in the regulation of various metabolic pathways. It is synthesized primarily in the enterocytes of the small intestine during fat absorption. After entry into the bloodstream, the 46-kDa glycoprotein apo A-IV appears associated with chylomicrons, high-density lipoproteins, and in the lipoprotein-free fraction. It has a role in lipid absorption, transport and metabolism, and may act as a post-prandial satiety signal, an anti-oxidant and a major factor in the prevention of atherosclerosis. After summarizing and discussing these functions for reader's comprehension, the current review focuses on the regulation of apo A-IV by nutrients, biliary components, drugs, hormones and gastrointestinal peptides. The understanding of the involved mechanisms that underline apo A-IV regulation may in the long run allow us to switch on its gene, which may confer multiple beneficial effects, including the protection from atherosclerosis. Show less
no PDF DOI: 10.1016/s1388-1981(03)00004-0
APOA4
Adebowale Adeyemo, Amy Luke, Richard Cooper +6 more · 2003 · Obesity research · Nature · added 2026-04-24
Interest in mapping genetic variants that are associated with obesity remains high because of the increasing prevalence of obesity and its complications worldwide. Data on genetic determinants of obes Show more
Interest in mapping genetic variants that are associated with obesity remains high because of the increasing prevalence of obesity and its complications worldwide. Data on genetic determinants of obesity in African populations are rare. We have undertaken a genome-wide scan for body mass index (BMI) in 182 Nigerian families that included 769 individuals. The prevalence of obesity was only 5%, yet polygenic heritability for BMI was in the expected range (0.46 +/- 0.07). Tandem repeat markers (402) were typed across the genome with an average map density of 9 cM. Pedigree-based analysis using a variance components linkage model demonstrated evidence for linkage on chromosome 7 (near marker D7S817 at 7p14) with a logarithm of odds (LOD) score of 3.8 and on chromosome 11 (marker D11S2000 at 11q22) with an LOD score of 3.3. Weaker evidence for linkage was found on chromosomes 1 (1q21, LOD = 2.2) and 8 (8p22, LOD = 2.3). Several candidate genes, including neuropeptide Y, DRD2, APOA4, lamin A/C, and lipoprotein lipase, lie in or close to the chromosomal regions where strong linkage signals were found. The findings of this study suggest that, as in other populations with higher prevalences of obesity, positive linkage signals can be found on genome scans for obesity-related traits. Follow-up studies may be warranted to investigate these linkages, especially the one on chromosome 11, which has been reported in a population at the opposite end of the BMI distribution. Show less
no PDF DOI: 10.1038/oby.2003.40
APOA4
Peggy Tilly, Catherine Sass, Monique Vincent-Viry +3 more · 2003 · Journal of lipid research · added 2026-04-24
Apolipoprotein C-III (apoC-III) is involved in triglycerides metabolism, and is therefore important for the pathogenesis of coronary heart diseases. However, to our knowledge serum apoC-III variation Show more
Apolipoprotein C-III (apoC-III) is involved in triglycerides metabolism, and is therefore important for the pathogenesis of coronary heart diseases. However, to our knowledge serum apoC-III variation factors and reference limits have never been determined, so the aim of this study was to establish them and facilitate clinical usefulness. We measured serum apoC-III concentration of apparently healthy subjects of the Stanislas Cohort by an immunoturbidimetric method. Genetic polymorphisms within the APOC3, APOE, APOAIV, and LPL genes were determined by a multiplex PCR. Serum apoC-III concentration varied from 28.2 mg/l to 225.8 mg/l in the overall sample and between subjects variability was about 30%. Factors influencing apoC-III concentration were age, BMI in adult men, alcohol consumption in adults, oral contraceptive intake in women, the post-pubescent status in boys. The APOC3 1100T allele in adult men and the APOC3 -455C allele in boys were associated with increased apoC-III concentration. The APOA4 360His allele was associated with decreased apoC-III concentration in women. We also established reference limits of serum apoC-III concentration according to age and gender. Show less
no PDF DOI: 10.1194/jlr.M200006-JLR200
APOA4
S Garasto, G Rose, F Derango +9 more · 2003 · Annals of human genetics · added 2026-04-24
The genes coding for apolipoprotein A1 (APOA1), apolipoprotein C3 (APOC3) and apolipoprotein A4 (APOA4) are tandemly organised within a short region on chromosome 11q23-q24. Polymorphisms of these gen Show more
The genes coding for apolipoprotein A1 (APOA1), apolipoprotein C3 (APOC3) and apolipoprotein A4 (APOA4) are tandemly organised within a short region on chromosome 11q23-q24. Polymorphisms of these genes have been extensively investigated in lipoprotein disorders and cardiovascular diseases, but poorly investigated in healthy ageing. The aim of this study was to describe possible modifications of the APOA1, APOC3, and APOA4 gene pool by cross-sectional studies carried out in a healthy ageing population whose ages ranged from 18 to 109 years (800 subjects, 327 males and 473 females, free of clinically manifested disease, and with emato-chemical parameters in the norm). APOA1-MspI-RFLP (-75 nt from the transcription starting site), APOC3-SstI-RFLP (3'UTR, 3238 nt), and APOA4-HincII-RFLP (Asp127/Ser127) were analysed according to age and sex. A significant age-related variation of the APOA1 gene pool was observed in males. An analysis of the allele average effect exerted by APOA1-MspI-RFLP A/P alleles (Absence/Presence of the restriction site) on lipidemic parameters in 46-80 year old males showed that allele A decreased, while allele P significantly increased, serum LDL-cholesterol. Unexpectedly, the P allele was over-represented in the group of the oldest old subjects, thus giving evidence of another "genetic paradox of centenarians". Show less
no PDF DOI: 10.1046/j.1469-1809.2003.00008.x
APOA4
Min Liu, Nick Maiorano, Ling Shen +7 more · 2003 · Physiology & behavior · Elsevier · added 2026-04-24
Rat apolipoprotein AIV (apo AIV) is a 43-kDa intestinal apolipoprotein that is important in lipid metabolism and the suppression of food intake. In this study, a full-length rat apo AIV was expressed Show more
Rat apolipoprotein AIV (apo AIV) is a 43-kDa intestinal apolipoprotein that is important in lipid metabolism and the suppression of food intake. In this study, a full-length rat apo AIV was expressed in Escherichia coli and purified in a bioactive form. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and mass spectrometric analysis revealed that the isolated recombinant protein has a molecular mass of approximately 43 kDa, similar to that of natural rat apo AIV. Immunoblot analysis and N-terminal amino acid sequencing confirmed the identity of the recombinant apo AIV protein as natural rat apo AIV. The recombinant protein was functional in lipoprotein binding assays. Biological activity was assessed behaviorally in that the recombinant protein suppressed food intake of fasted rats comparably to natural rat apo AIV. Neither native nor recombinant apo AIV elicited a conditioned taste aversion (CTA) at doses that suppress feeding. These results indicate that the recombinant apo AIV is structurally and functionally indistinguishable from rat natural apo AIV, making this overexpression and purification scheme a powerful tool for future structure and function studies. Show less
no PDF DOI: 10.1016/s0031-9384(02)00959-9
APOA4
Song Lu, Ying Yao, Heng Wang +3 more · 2003 · American journal of physiology. Gastrointestinal and liver physiology · added 2026-04-24
Dietary lipid acutely upregulates apolipoprotein (apo) A-IV expression by sevenfold at the pretranslational level in neonatal swine jejunum. To determine the mechanism of this regulation, two-day-old Show more
Dietary lipid acutely upregulates apolipoprotein (apo) A-IV expression by sevenfold at the pretranslational level in neonatal swine jejunum. To determine the mechanism of this regulation, two-day-old female swine received intraduodenal infusions of low- and high-triacylglycerol (TG) isocaloric diets for 24 h. Nuclear runoff assay confirmed apo A-IV gene transcriptional regulation by the high-TG diet. Footprinting analysis using the swine apo A-IV proximal promoter sequence (+14 to -246 bp) demonstrated three regions protected by the low-TG extracts. Of these three motifs, only ACCTTC showed 100% homology to the human sequence and was further studied. EMSA was performed using probes containing wild-type (WT) and mutant (M) motifs. A shift was noted with the low-TG nuclear extracts with the WT probe but not with the M probe. Excess unlabeled free WT probe competed out the shift, whereas the M probe did not. No significant shift occurred with either probe using high-TG extracts. These results suggest that a repressor protein binds to the ACCTTC motif and becomes unbound during lipid absorption, allowing transcriptional activation of the apo A-IV gene in newborn swine small intestine. Show less
no PDF DOI: 10.1152/ajpgi.00391.2002
APOA4
Roshni R Singaraja, Catherine Fievet, Graciela Castro +9 more · 2002 · The Journal of clinical investigation · added 2026-04-24
The ABC transporter ABCA1 plays a key role in the first steps of the reverse cholesterol transport pathway by mediating lipid efflux from macrophages. Previously, it was demonstrated that human ABCA1 Show more
The ABC transporter ABCA1 plays a key role in the first steps of the reverse cholesterol transport pathway by mediating lipid efflux from macrophages. Previously, it was demonstrated that human ABCA1 overexpression in vivo in transgenic mice results in a mild elevation of plasma HDL levels and increased efflux of cholesterol from macrophages. In this study, we determined the effect of overexpression of ABCA1 on atherosclerosis development. Human ABCA1 transgenic mice (BAC(+)) were crossed with ApoE(-/-) mice, a strain that spontaneously develop atherosclerotic lesions. BAC(+)ApoE(-/-) mice developed dramatically smaller, less-complex lesions as compared with their ApoE(-/-) counterparts. In addition, there was increased efflux of cholesterol from macrophages isolated from the BAC(+)ApoE(-/-) mice. Although the increase in plasma HDL cholesterol levels was small, HDL particles from BAC(+)ApoE(-/-) mice were significantly better acceptors of cholesterol. Lipid analysis of HDL particles from BAC(+)ApoE(-/-) mice revealed an increase in phospholipid levels, which was correlated significantly with their ability to enhance cholesterol efflux. Show less
no PDF DOI: 10.1172/JCI15748
APOA4
Puneet Pal Singh, Monica Singh, Sarabjit S Mastana · 2002 · Human biology · added 2026-04-24
Genetic variation at three apolipoprotein loci (APOA4, APOH, and APOE) has been examined in nine endogamous populations of Punjab, North India. The overall pattern of allele frequency variation at dif Show more
Genetic variation at three apolipoprotein loci (APOA4, APOH, and APOE) has been examined in nine endogamous populations of Punjab, North India. The overall pattern of allele frequency variation at different loci is compatible with that of European populations, but observed microvariation differentiates the populations according to their position in the Indian caste structure. The most common allele at the APOA4 locus was APOA4*1 with a narrow frequency range (89%-92%). APOH*2 allele frequency was highest in these populations (0.852-0.914). APOE*E4 allele frequency was relatively low (6%-10%) in the North Indian populations compared to its frequency in many European populations. The anthropological usage of these polymorphisms was evaluated using multivariate analyses. Genetic distance analysis and principal correspondence analysis showed that the North Indian populations are closest to Europeans, followed by Chinese and African populations. Overall, this study highlights the usefulness of apolipoproteins as genetic markers for clinical, population, and anthropological studies. Show less
no PDF DOI: 10.1353/hub.2002.0057
APOA4
Miriam Lee, Christian P Sommerhoff, Arnold von Eckardstein +3 more · 2002 · Arteriosclerosis, thrombosis, and vascular biology · added 2026-04-24
In human atherosclerotic lesions, degranulated mast cells are found in the vicinity of macrophage foam cells. Mast cell granules contain tryptase, a tetrameric serine protease requiring glycosaminogly Show more
In human atherosclerotic lesions, degranulated mast cells are found in the vicinity of macrophage foam cells. Mast cell granules contain tryptase, a tetrameric serine protease requiring glycosaminoglycans for stabilization. No endogenous inhibitors have been described for tryptase, and the physiological functions of the enzyme are poorly understood. Here, we investigated the effects of human tryptase on the integrity of high density lipoprotein (HDL)3 and on its ability to release cholesterol from cultured mouse macrophage foam cells. Incubation of HDL3 with tryptase led to degradation of its apolipoproteins. Tryptase predominantly degraded a quantitatively minor subfraction of HDL3 that is lipid poor, exhibits electrophoretic pre-beta mobility, and contains either apolipoprotein A-I or apolipoprotein A-IV as its sole apolipoprotein. Moreover, tryptase caused functional changes in HDL3 by destroying its ability to promote high-affinity efflux of cholesterol from macrophage foam cells, ie, the pre-beta-HDL-dependent component of the process. Human aortic proteoglycans increased the ability of tryptase to proteolyze HDL3, suggesting that the proteoglycan-rich extracellular matrix of the arterial intima provides an appropriate environment for the extracellular actions of tryptase. By depleting pre-beta-HDL, mast cell tryptase may impair the initial step of reverse cholesterol transport and will then favor cellular accumulation of cholesterol during atherogenesis. Show less
no PDF DOI: 10.1161/01.atv.0000041405.07367.b5
APOA4
Philippa J Talmud, Emma Hawe, Steve Martin +5 more · 2002 · Human molecular genetics · Oxford University Press · added 2026-04-24
Since triglycerides (TG) are a major independent risk factor for coronary heart disease, understanding their genetic and environmental determinants is of major importance. Mouse models indicate an inv Show more
Since triglycerides (TG) are a major independent risk factor for coronary heart disease, understanding their genetic and environmental determinants is of major importance. Mouse models indicate an inverse relationship between levels of the newly identified apolipoprotein AV (APOAV) and TG concentrations. We have examined the relative influence of human APOA5 variants on plasma lipids, compared to the impact of variation in APOC3 and APOA4 which lie in the same cluster. Single nucleotide polymorphisms (SNPs) in APOA5 (S19W, -1131T>C) and APOA4 (T347S, Q360H) and an APOA4/A5 intergenic T>C SNP were examined in a large study of healthy middle-aged men (n=2808). APOA5 19WW and -1131CC men had 52% and 40% higher TG (P<0.003) compared to common allele homozygotes, respectively, effects which were independent and additive. APOA4 347SS men had 23% lower TG compared to TT men (P<0.002). Haplotype analysis was carried out to identify TG-raising alleles and included, in addition, four previously genotyped APOC3 SNPs (-2845T>G, -482C>T, 1100C>T, and 3238C>G). The major TG-raising alleles were defined by APOA5 W19 and APOC3 -482T. This suggests that the TG-lowering effect of APOA4 S347 might merely reflect the strong negative linkage disequilibrium with the common alleles of these variants. Thus variation in APOA5 is associated with differences in TGs in healthy men, independent of those previously reported for APOC3, while association between APOA4 and TG reflects linkage disequilibrium with these sites. The molecular mechanisms for these effects remain to be determined. Show less
no PDF DOI: 10.1093/hmg/11.24.3039
APOA4
L K Li, S E Humphries, N Wood · 2002 · Atherosclerosis · Elsevier · added 2026-04-24
no PDF DOI: 10.1016/s0021-9150(02)00118-1
APOA4
G Miltiadous, M Hatzivassiliou, E Bashiardes +3 more · 2002 · Clinical genetics · added 2026-04-24
Apolipoprotein (apo) A-IV is a protein component of triglyceride-rich lipoproteins and high-density lipoproteins (HDL). In this study, two common genetic polymorphisms of the apoA-IV gene [codons 347( Show more
Apolipoprotein (apo) A-IV is a protein component of triglyceride-rich lipoproteins and high-density lipoproteins (HDL). In this study, two common genetic polymorphisms of the apoA-IV gene [codons 347(allele A and T) and 360 (allele 1 and 2)] were investigated in Greek patients with hyperlipidaemia and in healthy individuals matched for age, sex and smoking habits. In both study populations we evaluated the effect of these polymorphic sites on lipid and lipoprotein plasma levels and the body mass index (BMI). The frequencies of the 1/1 and 1/2 genotypes in codon 360 were 0.94 and 0.06 in hyperlipidemic patients and 0.92 and 0.08 in the control population, respectively. The frequencies of the A/A, A/T and T/T genotypes in codon 347 were 0.62, 0.34 and 0.04 in hyperlipidemic patients and 0.59, 0.33 and 0.08 in the control population, respectively. None of the above genotype frequency differences between the study populations reached statistical significance. The control population was not affected by any polymorphism of the apo A-IV gene. Hyperlipidaemic patients, carriers of the allele 2 (1/2 genotype), had significantly lower plasma triglyceride levels than carriers of the allele 1 (p = 0.03). Genetic variation in codon 347 had no influence on lipid and lipoprotein plasma levels. None of the polymorphisms at codons 360 and 347 affected the BMI. In conclusion, this study describes for the first time the genotype frequencies for polymorphic sites in codons 360 and 347 of the apo A-IV gene in a Greek population and suggests that the presence of the allele 2 is associated with lower plasma triglyceride levels in hyperlipidaemic patients. Show less
no PDF DOI: 10.1034/j.1399-0004.2002.620304.x
APOA4
I A Larson, J M Ordovas, Z Sun +5 more · 2002 · Clinical genetics · added 2026-04-24
The effects of apolipoprotein (apo) A-IV genotype on serum glucose, total cholesterol, low density lipoprotein (LDL) cholesterol, high density lipoprotein (HDL) cholesterol, triglyceride and glucose c Show more
The effects of apolipoprotein (apo) A-IV genotype on serum glucose, total cholesterol, low density lipoprotein (LDL) cholesterol, high density lipoprotein (HDL) cholesterol, triglyceride and glucose concentrations were ascertained in a population of 373 men and 361 women with a mean age of about 57 years. Subjects were evaluated at entry into a lifestyle intervention program. Apolipoprotein A-IV genotype variations at residues 347 and 360 were examined, as these mutations affect the sequence of apo A-IV, a major protein constituent of intestinal triglyceride-rich lipoprotein and HDL. With regard to the apo A-IV 360 mutation, 16.4% of the females and 13.4% of the males carried the apo A-IV 2-allele, almost entirely in the heterozygous state. No effect of the apo A-IV 1/2 genotype was observed in either men or women on total cholesterol, LDL cholesterol, HDL cholesterol, triglyceride, the total cholesterol (TC)/HDL ratio, or on A-I, A-IV and apo B levels. This was also the case for the apo A-IV 347 mutation. However, women with the apo A-IV 360 1/2 genotype had significantly (p < 0.005) higher glucose levels (105.5 mg/dl) compared with the 1/1 wild-type (94.0 mg/dl). All analyses were also adjusted for age, body mass index, medications, alcohol use and cigarette smoking. The prevalence of the 347 mutation was somewhat higher than the 360 mutation, with 29% of the females and 32.0% of the males being heterozygous for this mutation, and 3.9% of the females and 5.4% of the males being homozygous for this mutation. These data are consistent with the concept that the apo A-IV 360 and 347 genotypes have no significant effect on apo A-IV levels and other lipid parameters in either gender. However, apo A-IV 360 1/2 genotype did have a significant effect on serum glucose levels in women. Show less
no PDF DOI: 10.1034/j.1399-0004.2002.610606.x
APOA4
Dominique Sauvaget, Valérie Chauffeton, Danièle Citadelle +7 more · 2002 · The Journal of biological chemistry · American Society for Biochemistry and Molecular Biology · added 2026-04-24
The apoA-I/C-III/A-IV gene cluster, like most intestine-specific genes, displays a specific pattern of expression along the intestinal cephalocaudal and crypt-to-villus axes. We have shown that this s Show more
The apoA-I/C-III/A-IV gene cluster, like most intestine-specific genes, displays a specific pattern of expression along the intestinal cephalocaudal and crypt-to-villus axes. We have shown that this specific pattern of expression requires the distal apoA-IV promoter and the apoC-III enhancer. Using a new set of transgenic mice, we demonstrate here that the restriction of apoA-IV gene transcription to villus enterocytes requires a hormone-responsive element (HRE) located within the apoA-IV distal promoter. We showed, using nuclear extracts from villus or crypt epithelial cells, that this HRE bound the transcription factor hepatic nuclear factor 4 (HNF-4). We also found that the HNF-4gamma isoform was produced only in the villus, whereas the HNF-4alpha isoform was produced along the entire length of the crypt-to-villus axis. Our results demonstrate that the HRE of the distal apoA-IV promoter is responsible for the restriction of gene expression to villus epithelial cells and that this HRE binds HNF-4 isoforms. The in vivo observation of parallel gradients for apoA-IV and HNF-4gamma gene expression raises questions concerning whether this transcription factor plays a specific role in the control of enterocyte differentiation. Show less
no PDF DOI: 10.1074/jbc.M206074200
APOA4
Song Lu, Ying Yao, Songmai Meng +2 more · 2002 · The Journal of biological chemistry · American Society for Biochemistry and Molecular Biology · added 2026-04-24
Apolipoprotein A-IV (apoA-IV) has myriad functions, including roles as a post-prandial satiety factor and lipid antioxidant. ApoA-IV is expressed in mammalian small intestine and is up-regulated in re Show more
Apolipoprotein A-IV (apoA-IV) has myriad functions, including roles as a post-prandial satiety factor and lipid antioxidant. ApoA-IV is expressed in mammalian small intestine and is up-regulated in response to lipid absorption. In newborn swine jejunum, a high fat diet acutely induces a 7-fold increase in apoA-IV expression. To determine whether apoA-IV plays a role in the transport of absorbed lipid, swine apoA-IV was overexpressed in a newborn swine enterocyte cell line, IPEC-1, followed by analysis of the expression of genes related to lipoprotein assembly and lipid transport, as well as quantitation of lipid synthesis and secretion. A full-length swine apoA-IV cDNA was cloned, sequenced, and inserted into a Vp and Rep gene-deficient adeno-associated viral vector, containing the cytomegalovirus immediate early promoter/enhancer and neomycin resistance gene, and was used to transfect IPEC-1 cells. Control cells were transfected with the same vector minus the apoA-IV insert. Using neomycin selection, apoA-IV-overexpressing (+AIV) and control (-AIV) clones were isolated for further study. Both undifferentiated (-D) and differentiated (+D) +AIV cells expressed 40- to 50-fold higher levels of apoA-IV mRNA and both intracellular and secreted apoA-IV protein compared with -AIV cells. Expression of other genes was not affected by apoA-IV overexpression in a manner that would contribute to enhanced lipid secretion. +D +AIV cells secreted 4.9-fold more labeled triacylglycerol (TG), 4.6-fold more labeled cholesteryl ester (CE), and 2-fold more labeled phospholipid (PL) as lipoproteins, mostly in the chylomicron/very low density lipoprotein (VLDL) density range. ApoA-IV overexpression in IPEC-1 cells enhances basolateral TG, CE, and PL secretion in chylomicron/VLDL particles. This enhancement is not associated with up-regulation of other genes involved in lipid transport. ApoA-IV may play a role in facilitating enterocyte lipid transport, particularly in the neonate receiving a diet of high fat breast milk. Show less
no PDF DOI: 10.1074/jbc.M201418200
APOA4
Fanny Ferrer, Edith Bigot-Corbel, Patrick N'Guyen +2 more · 2002 · Clinical chemistry · added 2026-04-24
A reliable method for plasma would be useful to investigate the role of apolipoprotein (apo) AIV when associated with apo B-containing or triglyceride-rich lipoproteins. We used a sandwich ELISA to qu Show more
A reliable method for plasma would be useful to investigate the role of apolipoprotein (apo) AIV when associated with apo B-containing or triglyceride-rich lipoproteins. We used a sandwich ELISA to quantify lipoprotein B:AIV particles (Lp B:AIVf; lipoproteins containing at least apo B and apo AIV) in plasma. The method used microtiter plates coated with purified anti-apo B immunoglobulins that selectively retained apo B-containing particles. Lipoproteins containing both apo B and apo AIV were distinguished from those containing only apo B by use of a peroxidase-labeled anti-apo AIV antibody. These subspecies were revealed by ABTS reagent and further quantified by spectrophotometry. Results were expressed in mg/L apo AIV associated with apo B. This method was applied to samples with different cholesterol and triglyceride concentrations. The developed sandwich ELISA method identified and quantified Lp B:AIVf in plasma samples. Within- and between-run CVs were approximately 10%, and analytical recoveries were 95-107%. Results were not significantly influenced by addition of triglycerides or by storage at -20 degrees C (up to 9 months). Under these conditions, plasma Lp B:AIVf concentrations were statistically higher in hypercholesterolemic and mixed hyperlipidemic individuals (53 +/- 13 mg/L; P <0.001 and 70 +/- 18 mg/L; P <0.001, respectively) than in normolipidemic individuals (43 +/- 12 mg/L). Lp B:AIVf concentration appeared to be well correlated with total cholesterol, triglycerides, LDL-cholesterol, and apo B. These results were in contrast to total apo AIV, which was not different between dyslipidemic and normolipidemic individuals. The developed ELISA method for Lp B:AIVf in plasma combines specificity, reliability, and speed. The increase in Lp B:AIVf concentrations in various dyslipidemic states, together with a lack of change in total apo AIV concentrations, suggests a redistribution of apo AIV toward apo B-containing lipoproteins when these lipoproteins accumulate. Show less
no PDF
APOA4
Maria A Ostos, Delia Recalde, Nadine Baroukh +4 more · 2002 · The Journal of nutrition · Oxford University Press · added 2026-04-24
Fructose intake has increased steadily during the past two decades. The objective of this study was to determine the effect of fructose intake on lipid metabolism in apolipoprotein (apo) AI-CIII-AIV t Show more
Fructose intake has increased steadily during the past two decades. The objective of this study was to determine the effect of fructose intake on lipid metabolism in apolipoprotein (apo) AI-CIII-AIV transgenic (Tg) mice that have severe hypertriglyceridemia and moderate hypercholesterolemia. Tg and control mice were fed for 9 mo a commercial nonpurified diet and had free access to water or 250 g/L fructose solution. In Tg mice, fructose intake increased triglycerides and cholesterol but did not induce insulin resistance. There were no differences in human hepatic apo AI and apo CIII mRNA levels in fructose-fed mice compared with untreated mice, but apo AIV mRNA was greater, indicating a differential expression of the apo AI and apo AIV genes in response to dietary perturbations. Interestingly, the plasma concentration of the three human apolipoproteins was enhanced in fructose-fed Tg mice compared with untreated Tg mice. Our data suggest that long-term fructose consumption had strong adverse effects in this hyperlipidemic mouse model. Show less
no PDF DOI: 10.1093/jn/132.5.918
APOA4
J Plat, R P Mensink · 2002 · European journal of clinical investigation · added 2026-04-24
Differences in genetic constitution may affect cholesterol metabolism and responses to diet. Identification of common variations in genes related to dietary responsiveness is therefore an attractive g Show more
Differences in genetic constitution may affect cholesterol metabolism and responses to diet. Identification of common variations in genes related to dietary responsiveness is therefore an attractive goal to be able to prescribe individually tailored diets for the treatment of dyslipidaemia. We have examined relationships between serum lipids and lipoproteins, cholesterol-standardized campesterol and lathosterol concentrations with genetic variation, and the presence of a gene-diet interaction between plant stanol ester consumption. Candidate genes were apolipoprotein A-IV (apoA-IV), scavenger receptor-BI (SR-BI), cholesterol ester transfer protein (CETP), 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, and apolipoprotein E (apoE). These relations were examined in 112 nonhypercholesterolaemic subjects, of whom 70 consumed 3.8-4.0 g plant stanol esters a day for 8 weeks. At baseline, high-density lipoprotein (HDL) concentrations of 1.56 +/- 0.36 mmol L(-1) in SR-BI-2 allele carriers tended to be lower compared to the 1.72 +/- 0.42 mmol L(-1) in SR-BI-1/1 subjects (P = 0.069). Cholesterol standardized lathosterol concentrations were also lower in the SR-BI-2 allele carriers (P = 0.002). Furthermore, low-density lipoprotein (LDL) cholesterol concentrations in apoE2 subjects, were lower compared to the LDL cholesterol concentration in apoE3 group (P = 0.002) and apoE4 subjects (P < 0.001). No significant differences between the polymorphisms and dietary responsiveness to plant stanol ester consumption could be found, which indicates that it is unlikely that one of the single polymorphisms analysed in this study is a major factor in explaining the variation in serum LDL cholesterol responses. These findings suggest that all subjects who want to lower their cholesterol concentration, will benefit from plant stanol ester consumption, irrespective of their apoA-IV, SR-BI, HMG-CoA reductase, CETP, or apoE genotype. Show less
no PDF DOI: 10.1046/j.1365-2362.2002.00982.x
APOA4
Huai Bai, Rui Liu, Yu Liu +1 more · 2002 · Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics · added 2026-04-24
The aim of this study was to investigate variations of apolipoprotein A IV (apo A IV) gene and its relation to endogenous hypertriglyceridemia(HTG) in Chinese population. One hundred and six endogenou Show more
The aim of this study was to investigate variations of apolipoprotein A IV (apo A IV) gene and its relation to endogenous hypertriglyceridemia(HTG) in Chinese population. One hundred and six endogenous hypertriglyceridemics and 171 healthy subjects from a population of Chinese Han nationality in Chengdu area were studied using restriction fragment length polymorphisms (RFLPs) and sequencing of apoA IV gene amplified by polymerase chain reaction (PCR). The polymorphic sites of apo A IV gene studied included codon 9 (A to G, synonymous mutation), codon 347 (A to T, non-synonymous mutation), codon 360 (G to T, non-synonymous mutation), and Msp I polymorphism (CC/TGG) within intron 2. The frequency of G allele at codon 9 in HTG group was higher than that in healthy controls(0.453 vs 0.366, P<0.05). The other polymorphic sites showed no significant differences of the allele frequencies between the two groups. The frequencies of rare alleles, such as G allele at codon 9, T allele at codon 347 and T allele at codon 360 polymorphic site were significantly different from those reported in European Caucasians (0.366 vs 0.032, P<0.001, 0.000 vs 0.160, P<0.001; 0.000 vs 0.070, P<0.001), but no differences were found when compared with those in Japanese, including Msp I site (P>0.05). In the healthy male control group, subjects with genotype G/G of codon 9 had a higher serum mean concentration of apoA I when compared with that of genotype A/A(P<0.01). In the HTG group, subjects with genotype C/T of Msp I site had a higher serum mean concentration of TG with compared with those with genotype C/C and T/T (P<0.05). This difference was only observed in male HTG group when male and female subgroups were further separated. These results suggest that Msp I and codon 9 polymorphism in apoA IV gene are associated with endogenous hypertriglyceridemia to some extent in Chinese population. Show less
no PDF
APOA4
Richard B Weinberg, Rachel A Anderson, Victoria R Cook +4 more · 2002 · The Journal of biological chemistry · American Society for Biochemistry and Molecular Biology · added 2026-04-24
We used a panel of recombinant human apolipoprotein (apo) A-IV truncation mutants, in which pairs of 22-mer alpha-helices were sequentially deleted along the primary sequence, to examine the impact of Show more
We used a panel of recombinant human apolipoprotein (apo) A-IV truncation mutants, in which pairs of 22-mer alpha-helices were sequentially deleted along the primary sequence, to examine the impact of protein structure and interfacial activity on the ability of apoA-IV to activate cholesterol ester transfer protein. Circular dichroism and fluorescence spectroscopy revealed that the secondary structure, conformation, and molecular stability of recombinant human apoA-IV were identical to the native protein. However, deletion of any of the alpha-helical domains in apoA-IV disrupted its tertiary structure and impaired its molecular stability. Surprisingly, determination of the water/phospholipid interfacial exclusion pressure of the apoA-IV truncation mutants revealed that, for most, deletion of amphipathic alpha-helical domains increased their affinity for phospholipid monolayers. All of the truncation mutants activated the transfer of fluorescent-labeled cholesterol esters between high and low density lipoproteins at a rate higher than native apoA-IV. There was a strong positive correlation (r = 0.790, p = 0.002) between the rate constant for cholesterol ester transfer and interfacial exclusion pressure. We conclude that molecular interfacial exclusion pressure, rather than specific helical domains, determines the degree to which apoA-IV, and likely other apolipoproteins, facilitate cholesterol ester transfer protein-mediated lipid exchange. Show less
no PDF DOI: 10.1074/jbc.M202197200
APOA4
Richard B Weinberg · 2002 · Current opinion in lipidology · added 2026-04-24
Apolipoprotein A-IV is a 46kDa glycoprotein that is synthesized by intestinal enterocytes and is incorporated into the surface of nascent chylomicrons. Considerable evidence suggests that apolipoprote Show more
Apolipoprotein A-IV is a 46kDa glycoprotein that is synthesized by intestinal enterocytes and is incorporated into the surface of nascent chylomicrons. Considerable evidence suggests that apolipoprotein A-IV plays a role in intestinal lipid absorption and chylomicron assembly. We have proposed that polymorphisms that alter the interfacial behavior of apolipoprotein A-IV may modulate the physical properties and metabolic fate of plasma chylomicrons. Of the reported genetic polymorphisms of apolipoprotein A-IV, two, Q360H and T347S, are known to occur at high frequencies among the world populations. Biophysical studies have established that the Q360H isoprotein displays higher lipid affinity; conversely the T347S isoprotein is predicted to be less lipid avid. Recent studies have shown that the Q360H polymorphism is associated with increased postprandial hypertriglyceridemia, a reduced low-density lipoprotein response to dietary cholesterol in the setting of a moderate fat intake, an increased high-density lipoprotein response to changes in total dietary fat content, and lower body mass and adiposity; the T347S polymorphism appears to confer the opposite effects. Studies on the diet-gene interactions of other apolipoprotein A-IV alleles are needed, as are studies on the interactions between apolipoprotein A-IV alleles and other apolipoprotein polymorphisms. Show less
no PDF DOI: 10.1097/00041433-200204000-00003
APOA4
George Miltiadous, Marios A Cariolou, Moses Elisaf · 2002 · Annals of clinical and laboratory science · added 2026-04-24
Familial hypercholesterolemia (FH) is the most common genetic disorder leading to premature atherosclerosis. Typically, it is due to mutations in the LDL receptor gene resulting in elevated total and Show more
Familial hypercholesterolemia (FH) is the most common genetic disorder leading to premature atherosclerosis. Typically, it is due to mutations in the LDL receptor gene resulting in elevated total and LDL cholesterol levels. The type of the LDL receptor gene mutations may affect the severity of hypercholesterolemia and consequently the incidence of coronary atherosclerosis. Furthermore, high-density lipoprotein (HDL) cholesterol levels have been recently shown to be an independent risk factor for coronary heart disease in this population. We examined the effect of the type of the LDL receptor gene mutations and of common gene polymorphisms possibly affecting HDL metabolism [cholesterol ester transfer protein (CETP), apolipoprotein A-IV (ApoA-IV), angiotensin converting enzyme (ACE), and apolipoprotein E (ApoE)] on HDL cholesterol levels in patients with molecularly defined heterozygous FH who were attending our lipid clinic (n=84). The nature of the LDL receptor gene mutation (81T>G, n=12; 858C>A, n=13; 1285G>A, n=12; 1646G>A, n=22; and 1775G>A, n=25) did not significantly influence HDL cholesterol levels. Unlike other gene polymorphisms, the apolipoprotein (apo) E gene polymorphism did significantly affect these levels. In fact, the presence of the E4 allele was associated with lower HDL cholesterol levels compared to patients not carrying this allele. We conclude that HDL cholesterol levels in heterozygous FH patients may be affected by the apoE gene polymorphism. Show less
no PDF
APOA4
G Ferretti, T Bacchetti, V Bicchiega +1 more · 2002 · Chemistry and physics of lipids · Elsevier · added 2026-04-24
Recent studies have demonstrated that Apo AIV exerts a protective effect against atherosclerosis. Moreover, Qin et al. (Am. J. Physiol. 274 (1998) H1836) have demonstrated that Apo AIV, isolated from Show more
Recent studies have demonstrated that Apo AIV exerts a protective effect against atherosclerosis. Moreover, Qin et al. (Am. J. Physiol. 274 (1998) H1836) have demonstrated that Apo AIV, isolated from rat plasma, exerts an inhibitory effect against Cu(2+)-induced lipid peroxidation of intestinal lymph and LDL. The aim of the study was to investigate whether human Apo AIV exerts a protective effect against Cu(2+)-induced lipid peroxidation. Our results demonstrated that human Apo AIV exerted an inhibitory effect against Cu(2+) and AAPH induced lipid peroxidation of VLDL, as shown by the lower increase in the levels of TBARS and conjugated dienes in lipoproteins preincubated with Apo AIV. In addition, the tryptophan (Trp) and probe 2-(dimethylamino)-6-lauroylnaphthalene (Laurdan) fluorescence studies demonstrated that the modifications of spectral properties in both lipoproteins preincubated with Apo AIV were lower with respect to ox-lipoproteins, suggesting that Apo AIV prevents the modification of physico-chemical properties due to peroxidation. Show less
no PDF DOI: 10.1016/s0009-3084(01)00201-8
APOA4